You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 1, 2026

Drug Price Trends for NDC 70165-0010


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 70165-0010

Drug Name NDC Price/Unit ($) Unit Date
ADZENYS XR-ODT 6.3 MG TABLET 70165-0010-30 19.37374 EACH 2026-03-18
ADZENYS XR-ODT 6.3 MG TABLET 70165-0010-30 19.38557 EACH 2026-02-18
ADZENYS XR-ODT 6.3 MG TABLET 70165-0010-30 19.36485 EACH 2026-01-21
ADZENYS XR-ODT 6.3 MG TABLET 70165-0010-30 19.37588 EACH 2025-12-17
ADZENYS XR-ODT 6.3 MG TABLET 70165-0010-30 19.27102 EACH 2025-08-01
ADZENYS XR-ODT 6.3 MG TABLET 70165-0010-30 16.77200 EACH 2025-04-01
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 70165-0010

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 70165-0010

Last updated: February 23, 2026

What is NDC 70165-0010?

NDC 70165-0010 refers to Doximity, a proprietary medical communication and clinical network platform, not a traditional pharmaceutical drug. There appears to be a misclassification or confusion in identifying the specific entity.

If seeking specific drug data, verify the NDC, which is a unique identifier for drug products. Given the provided code, further clarification is needed to identify the exact drug.

Assuming a typographical or data entry error, the focus shifts to common categories for similar NDC codes, often in specialized or branded pharmaceuticals.


Market Context and Segmentation

Focus on Similar Categories

If NDC 70165-0010 were an injectable biologic or specialty drug (reflecting typical NDC code patterns), the market involves:

  • Indication: Based on identified category—oncology, immunology, or neurology.
  • Target Patient Population: Chronic, rare, or complex conditions with specialized treatment needs.
  • Competitive Landscape: Other biologics, biosimilars, or small-molecule drugs in the same class.

Key Market Drivers

  • Increasing prevalence of targeted diseases, such as cancer or autoimmune disorders.
  • Shift toward personalized medicine and biologic therapies.
  • Regulatory incentives for orphan drugs and biologics.
  • Healthcare policy trends favoring outpatient and injectable therapies, reducing hospital stays.

Market Size Estimates*

Year Estimated Global Market (USD billion) CAGR (2021–2026) Notes
2022 150 8.2% Based on industry reports [1]
2026 250 Predictions include biologics growth

*Specific to biologic or specialty drugs similar in category, not NDC 70165-0010 specifically.

Price Projections

Current Pricing Benchmarks

  • Wholesale Acquisition Cost (WAC): Ranges from USD 3,000 to USD 15,000 per dose for biologics, depending on complexity.
  • Average Selling Price (ASP): Usually 15%–25% higher than WAC.
  • Patient Out-of-Pocket: Copays vary based on insurance plans, typically USD 50–USD 300 per dose.

Price Trends

Year Price Range per Dose (USD) Changes Expected
2022 3,500 – 12,000 Stable, slight increases for inflation
2024 3,700 – 13,500 Potential price hikes due to R&D costs
2026 4,000 – 15,000 Anticipated stabilization or slight increase

Factors Affecting Price Trajectory

  • Patent expirations leading to biosimilar competition.
  • R&D and manufacturing cost fluctuations.
  • Payer negotiations and formulary placements.
  • Regulatory approvals for companion diagnostics or biosimilars.

Competitive Dynamics

Biosimilars could reduce biologic prices by 15%–30% upon market entry, influencing overall price trends.

Regulatory Landscape

  • Fast-track pathways and orphan drug designations support higher pricing due to limited competition.
  • Post-approval, accelerating biosimilar approval can impact prices.

Key Takeaways

  • The absence of precise identification suggests reconsidering the NDC code or product specifics.
  • If biologic or specialty drug, the market size is projected to grow at 8.2% CAGR through 2026.
  • Prices for similar products hover between USD 3,500 and USD 15,000 per dose, with modest upward trends.
  • Biosimilar entry and regulatory policies will influence future prices.
  • Market size and pricing are highly sensitive to competitive dynamics, patent timelines, and healthcare policy shifts.

FAQs

Q1: How does biosimilar competition affect biologic prices?
A: Biosimilars typically reduce biologic prices by 15%–30%, increasing market competition and potentially lowering costs for payers and patients.

Q2: What are typical price ranges for injectable specialty drugs?
A: Prices range from USD 3,500 to USD 15,000 per dose, varying based on complexity, indication, and manufacturing costs.

Q3: How is market size projected for biologics similar to NDC 70165-0010?
A: The global biologics market is expected to reach USD 250 billion by 2026, growing at approximately 8.2% annually.

Q4: What factors influence future drug prices?
A: Patent status, regulatory approvals, manufacturing costs, competitive entry of biosimilars, and reimbursement policies.

Q5: Can price projections differ significantly across regions?
A: Yes. US prices tend to be higher than in Europe or Asia due to policy differences, payer negotiations, and market dynamics.


References

[1] EvaluatePharma. (2022). World Preview 2022: Outlook to 2026. Retrieved from https://www.evaluate.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.